Exelixis Inc (EXEL)
22.88
+0.06
(+0.24%)
USD |
NASDAQ |
Apr 17, 16:00
22.88
0.00 (0.00%)
After-Hours: 20:00
Exelixis Research and Development Expense (Quarterly): 244.67M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 244.67M |
| September 30, 2023 | 332.58M |
| June 30, 2023 | 232.57M |
| March 31, 2023 | 234.25M |
| December 31, 2022 | 336.82M |
| September 30, 2022 | 198.84M |
| June 30, 2022 | 199.48M |
| March 31, 2022 | 156.67M |
| December 31, 2021 | 222.27M |
| September 30, 2021 | 163.37M |
| June 30, 2021 | 148.79M |
| March 31, 2021 | 159.29M |
| December 31, 2020 | 154.28M |
| September 30, 2020 | 176.76M |
| June 30, 2020 | 114.93M |
| March 31, 2020 | 101.88M |
| December 31, 2019 | 94.45M |
| September 30, 2019 | 97.30M |
| June 30, 2019 | 81.93M |
| March 31, 2019 | 63.29M |
| December 31, 2018 | 57.27M |
| September 30, 2018 | 44.74M |
| June 30, 2018 | 42.49M |
| March 31, 2018 | 37.76M |
| December 31, 2017 | 32.20M |
| Date | Value |
|---|---|
| September 30, 2017 | 28.54M |
| June 30, 2017 | 28.21M |
| March 31, 2017 | 23.21M |
| December 31, 2016 | 23.80M |
| September 30, 2016 | 20.26M |
| June 30, 2016 | 22.98M |
| March 31, 2016 | 28.93M |
| December 31, 2015 | 23.47M |
| September 30, 2015 | 26.09M |
| June 30, 2015 | 24.51M |
| March 31, 2015 | 22.28M |
| December 31, 2014 | 39.65M |
| September 30, 2014 | 43.63M |
| June 30, 2014 | 50.98M |
| March 31, 2014 | 54.85M |
| December 31, 2013 | 49.60M |
| September 30, 2013 | 47.35M |
| June 30, 2013 | 49.08M |
| March 31, 2013 | 32.74M |
| December 31, 2012 | 32.49M |
| September 30, 2012 | 30.68M |
| June 30, 2012 | 32.61M |
| March 31, 2012 | 33.10M |
| December 31, 2011 | 30.78M |
| September 30, 2011 | 37.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
81.93M
Minimum
Jun 2019
336.82M
Maximum
Dec 2022
181.64M
Average
163.37M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | 1.177B |
| Bristol-Myers Squibb Co | 2.478B |
| Incyte Corp | 444.49M |
| Bio-Techne Corp | 22.92M |
| Legend Biotech Corp | 105.68M |